Dr Bacopoulos’s previous leadership roles include CEO and president of Aton Pharma, where he led the development of Zolinza, approved for the treatment of cutaneous T-cell lymphoma.
Dr Bacopoulos has received his BA degree from Cornell College and his PhD from the University of Iowa. Dr Bacopoulos has completed additional coursework and obtained a postdoctoral fellowship at Yale University School of Medicine.
Spiro Rombotis, president and CEO of Cyclacel, said: “Nicholas Bacopoulos is a valuable addition to Cyclacel’s board of directors bringing extensive knowledge and understanding of the field of oncology.
“His experience with commercialization and product development makes him a strong resource as we advance our clinical pipeline, including our lead drug candidate sapacitabine, currently in Phase II trials for the treatment of elderly patients with acute myeloid leukemia.”